[Skip to Content]
[Skip to Content Landing]
July 19, 1971

Retroperitoneal Lymphadenectomy for Testicular Tumors

Author Affiliations

From the Department of Surgery, Division of Urology (Drs. Walsh, Kaufman, and Goodwin), and the Department of Pathology (Dr. Coulson), UCLA School of Medicine, and the Department of Surgery, Division of Urology, Wadsworth Veterans Administration Hospital, Los Angeles.

JAMA. 1971;217(3):309-312. doi:10.1001/jama.1971.03190030035007

Sixty-four patients have been observed for three years or more after radical lymphadenectomy for nonseminomatous germinal-cell tumors of the testis. The results of this study indicate that survival rates of patients with stage A teratocarcinoma and embryonal carcinoma were excellent (93% and 94%, respectively). In patients with stage B tumors, survival rates were far better in the teratocarcinoma group (77%) than in patients with embryonal carcinoma (29%). The study failed to document the value of postlymphadenectomy radiation therapy for either embryonal carcinoma or teratocarcinoma. Furthermore, there appears to be no advantage to bilateral lymphadenectomy over unilateral lymph-node dissection. Results from studies employing either the lumbar approach or transperitoneal approach appear to be equal.